A client with treatment-resistant schizophrenia is starting … | MyMerci
Medical Emergencies PA
Question

A client with treatment-resistant schizophrenia is starting clozapine. Which baseline laboratory test must be documented before each dispensing of the medication?

Explanation
Correct (2): Clozapine carries a boxed warning for severe agranulocytosis (~1% incidence). The Clozapine REMS program requires documented ANC ≥1500/mm³ before each dispense — weekly for the first 6 months, biweekly months 7-12, then monthly thereafter. The drug must be held if ANC

In-depth explanation

Memory Tip "Clozapine = ANC clock" — weekly × 6 months, biweekly × 6 months, then monthly. Caution Clients must report fever, sore throat, mouth ulcers, or flu-like symptoms IMMEDIATELY — infection during clozapine-induced neutropenia can be fatal. Clinical Practice Guide Pharmacies cannot dispense without a current ANC documented in REMS; missed labs interrupt therapy.

Clinical scenario

Scenario A 28-year-old male with treatment-resistant schizophrenia has failed adequate trials of olanzapine and risperidone. The provider prescribes clozapine 12.5 mg PO BID with a planned titration. REMS program enrollment is complete and the pharmacy is awaiting clearance to dispense.

Key concepts

Browse all questions No login required

Master the NCLEX-RN with MyMerci

Thousands of NCLEX-style questions with detailed rationale — in your language. Track your progress and study smarter.

Start for free
Read in another language: English한국어日本語繁體中文Tiếng Việt

For study reference only. Always follow current clinical guidelines and your institution’s protocols.